These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18193353)

  • 1. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
    Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
    Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of HER2 overexpression in metastatic malignant melanoma.
    Inman JL; Kute T; White W; Pettenati M; Levine EA
    J Surg Oncol; 2003 Oct; 84(2):82-8. PubMed ID: 14502781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
    Going JJ
    Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
    Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
    Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
    J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.